File Download
Supplementary

Conference Paper: Prognostic factors for adenocarcinoma of esophagogastric junction

TitlePrognostic factors for adenocarcinoma of esophagogastric junction
Authors
Issue Date2011
PublisherSociety for Surgery of the Alimentary Tract.
Citation
The 52nd Annual Meeting of the Society for Surgery of the Alimentary Tract (SSAT), Chicago, IL., 6-10 May 2011 during Digestive Disease Week How to Cite?
AbstractINTRODUCTION: The incidence of Barrett’s esophagus is low in Chinese population. Most of our patients who have adenocarcinomas of the esophagogastric junction (AEG) are Siewert type II or III. This study aims to evaluate the outcome after surgical resection in this group of patients, comparing clinicopathological differences between type II and III cancers, and identify prognostic factors. Material and METHODS: Patients who underwent resection for AEG tumors between 1995 and 2008 were included. Those with Siewert type I cancers were excluded. Data were retrieved from a prospectively collected database. Patient characteristics and clinicopathological data and outcome were evaluated. RESULTS: There were 126 patients (99 men, 27 women). The median age was 70 yrs (range: 23-87). Type II tumors were found in 65 patients and type III in 61. Thoracotomy was required for tumor extirpation in 50 (76.9%) and 34 (55.7%) patients, respectively (p=0.014). The operative blood loss was higher for type III tumors (median 300 ml vs. 400ml, p=0.005). There was no hospital mortality. Type III AEG was associated with significantly higher incidence of poorly differentiated cancer (44.6% vs. 73.8%, p=0.003), higher number of nodal metastasis (median 3 vs. 7, p=0.031), and advanced TNM stage (stage IIIA-IV disease in 64.6% vs. 86.9%, p=0.004). Overall median survival for the whole group was 17 months. Patients with type II AEG had longer survival (37.6 vs. 10.4 months), (p<0.01). Independent variables identified by Cox regression model for better survival were Siewert type II (p=0.021), earlier N-stage (p<0.01) and R0 resection (p<0.01).CONCLUSION: Type III AEG tumors were more likely to be poorly differentiated, more advanced and had worse survival compared to type II AEG cancers. Other independent prognostic factors were N-stage and R-category of resection.
DescriptionPoster Session - Clinical: Esophageal: P38
Persistent Identifierhttp://hdl.handle.net/10722/136087

 

DC FieldValueLanguage
dc.contributor.authorChan, FSYen_US
dc.contributor.authorTong, DKHen_US
dc.contributor.authorWong, KHen_US
dc.contributor.authorLaw, Sen_US
dc.date.accessioned2011-07-27T02:02:38Z-
dc.date.available2011-07-27T02:02:38Z-
dc.date.issued2011en_US
dc.identifier.citationThe 52nd Annual Meeting of the Society for Surgery of the Alimentary Tract (SSAT), Chicago, IL., 6-10 May 2011 during Digestive Disease Weeken_US
dc.identifier.urihttp://hdl.handle.net/10722/136087-
dc.descriptionPoster Session - Clinical: Esophageal: P38-
dc.description.abstractINTRODUCTION: The incidence of Barrett’s esophagus is low in Chinese population. Most of our patients who have adenocarcinomas of the esophagogastric junction (AEG) are Siewert type II or III. This study aims to evaluate the outcome after surgical resection in this group of patients, comparing clinicopathological differences between type II and III cancers, and identify prognostic factors. Material and METHODS: Patients who underwent resection for AEG tumors between 1995 and 2008 were included. Those with Siewert type I cancers were excluded. Data were retrieved from a prospectively collected database. Patient characteristics and clinicopathological data and outcome were evaluated. RESULTS: There were 126 patients (99 men, 27 women). The median age was 70 yrs (range: 23-87). Type II tumors were found in 65 patients and type III in 61. Thoracotomy was required for tumor extirpation in 50 (76.9%) and 34 (55.7%) patients, respectively (p=0.014). The operative blood loss was higher for type III tumors (median 300 ml vs. 400ml, p=0.005). There was no hospital mortality. Type III AEG was associated with significantly higher incidence of poorly differentiated cancer (44.6% vs. 73.8%, p=0.003), higher number of nodal metastasis (median 3 vs. 7, p=0.031), and advanced TNM stage (stage IIIA-IV disease in 64.6% vs. 86.9%, p=0.004). Overall median survival for the whole group was 17 months. Patients with type II AEG had longer survival (37.6 vs. 10.4 months), (p<0.01). Independent variables identified by Cox regression model for better survival were Siewert type II (p=0.021), earlier N-stage (p<0.01) and R0 resection (p<0.01).CONCLUSION: Type III AEG tumors were more likely to be poorly differentiated, more advanced and had worse survival compared to type II AEG cancers. Other independent prognostic factors were N-stage and R-category of resection.-
dc.languageengen_US
dc.publisherSociety for Surgery of the Alimentary Tract.-
dc.relation.ispartofAnnual Meeting of the Society for Surgery of the Alimentary Tract, SSAT 2011en_US
dc.relation.ispartofDigestive Disease Week 2011-
dc.titlePrognostic factors for adenocarcinoma of esophagogastric junctionen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, FSY: fsychan@hku.hken_US
dc.identifier.emailTong, DKH: esodtong@hku.hken_US
dc.identifier.emailLaw, S: slaw@hku.hken_US
dc.identifier.authorityLaw, S=rp00437en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros186145en_US
dc.publisher.placeUnited States-
dc.description.otherThe 52nd Annual Meeting of the Society for Surgery of the Alimentary Tract (SSAT), Chicago, IL., 6-10 May 2011 during Digestive Disease Week-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats